Inventor · disambiguated record
Daniel Dix
Also filed as: DIX DANIEL · DIX DANIEL B
49 granted patents·22 pending applications·1,853 citations·filing 2005–2025
99Inventor score
Top patents by PatentIndex Score
71 records- 0199US11084865B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2020·Granted Aug 10, 2021·14 cites·64 claims
- 0299US10464992B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2018·Granted Nov 5, 2019·60 cites·18 claims
- 0399US10406226B2Method of manufacturing VEGF antagonist fusion proteinsREGENERON PHARMA·Filed 2017·Granted Sep 10, 2019·70 cites·4 claims
- 0499US10400025B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2018·Granted Sep 3, 2019·54 cites·15 claims
- 0599US9914763B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2016·Granted Mar 13, 2018·56 cites·12 claims
- 0699US9636400B2VEGF specific fusion protein antagonist formulationsREGENERON PHARMA·Filed 2016·Granted May 2, 2017·59 cites·27 claims
- 0799US9580489B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2016·Granted Feb 28, 2017·67 cites·29 claims
- 0899US9340594B2VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2014·Granted May 17, 2016·73 cites·12 claims
- 0999US8802107B2VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2013·Granted Aug 12, 2014·65 cites·18 claims
- 1099US7807164B2Lyophilized VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2009·Granted Oct 5, 2010·83 cites·9 claims
- 1198US11066458B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2019·Granted Jul 20, 2021·12 cites·66 claims
- 1298US10857231B2Formulations of VEG antagonist fusion proteins and method of manufacturing themREGENERON PHARMA·Filed 2019·Granted Dec 8, 2020·9 cites·114 claims
- 1398US9511140B2Stable VEGF antagonist formulationsREGENERON PHARMA·Filed 2016·Granted Dec 6, 2016·62 cites·8 claims
- 1498US9416167B2Stable liquid formulations of dimer VEGF antagonistsREGENERON PHARMA·Filed 2014·Granted Aug 16, 2016·62 cites·8 claims
- 1598US8921316B2Stable liquid VEGF antagonist formulationsREGENERON PHARMA·Filed 2013·Granted Dec 30, 2014·62 cites·2 claims
- 1698US8710004B2Stable liquid VEGF antagonist formulationsDIX DANIEL·Filed 2012·Granted Apr 29, 2014·60 cites·6 claims
- 1798US8481046B2VEGF antagonist formulations for intravitreal administrationFURFINE ERIC·Filed 2011·Granted Jul 9, 2013·72 cites·9 claims
- 1898US8404638B2Dimer VEGF antagonist formulationsDIX DANIEL·Filed 2012·Granted Mar 26, 2013·62 cites·8 claims
- 1998US8110546B2VEGF antagonist formulationsDIX DANIEL·Filed 2010·Granted Feb 7, 2012·75 cites·5 claims
- 2098US8092803B2VEGF antagonist formulations for intravitreal administrationFURFINE ERIC·Filed 2010·Granted Jan 10, 2012·136 cites·19 claims
- 2197US11732024B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2021·Granted Aug 22, 2023·2 cites·60 claims
- 2297US10752701B2Stabilized formulations containing anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2019·Granted Aug 25, 2020·8 cites·21 claims
- 2397US9173880B2Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodiesDIX DANIEL B·Filed 2011·Granted Nov 3, 2015·96 cites·17 claims
- 2497US8795669B2Stabilized formulations containing anti-PCSK9 antibodiesWALSH SCOTT·Filed 2012·Granted Aug 5, 2014·44 cites·16 claims
- 2597US7608261B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMACUTICALS INC·Filed 2007·Granted Oct 27, 2009·131 cites·17 claims
- 2696US9402898B2Stabilized formulations containing anti-Ang2 antibodiesWALSH SCOTT M·Filed 2013·Granted Aug 2, 2016·79 cites·34 claims
- 2796US8945559B2Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodiesDIX DANIEL B·Filed 2011·Granted Feb 3, 2015·139 cites·25 claims
- 2895US12331099B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2024·Granted Jun 17, 2025·0 cites·30 claims
- 2995US10435473B2Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodiesREGENERON PHARMA·Filed 2017·Granted Oct 8, 2019·18 cites·21 claims
- 3095US10342876B2Process for reducing subvisible particles in a pharmaceutical formulationREGENERON PHARMA·Filed 2015·Granted Jul 9, 2019·17 cites·21 claims
- 3195US9238692B2Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodiesREGENERON PHARMA·Filed 2014·Granted Jan 19, 2016·26 cites·22 claims
- 3294US10472425B2Stabilized formulations containing anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2017·Granted Nov 12, 2019·12 cites·8 claims
- 3393US10072086B2Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodiesREGENERON PHARMA·Filed 2015·Granted Sep 11, 2018·12 cites·26 claims
- 3493US9193801B2Stabilized formulations containing anti-PCSK9 antibodiesREGENERON PHARMA·Filed 2014·Granted Nov 24, 2015·25 cites·22 claims
- 3592US11059896B2Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodiesREGENERON PHARMA·Filed 2019·Granted Jul 13, 2021·3 cites·45 claims
- 3690US11926670B2Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodiesREGENERON PHARMA·Filed 2021·Granted Mar 12, 2024·1 cites·23 claims
- 3790US11806398B2Citrate buffered VEGF antagonist formulationsREGENERON PHARMA·Filed 2020·Granted Nov 7, 2023·1 cites·28 claims
- 3890US7572893B2IL-1 antagonist formulationsREGENERON PHARMA·Filed 2007·Granted Aug 11, 2009·11 cites·19 claims
- 3990US2023374108A1Vegf antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4089US2024360230A1Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) AntibodiesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4187US7655758B2Stable liquid IL-1 antagonist formulationsREGENERON PHARMA·Filed 2008·Granted Feb 2, 2010·6 cites·12 claims
- 4287US2025197515A1Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodiesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4387US2025257118A1Vegf antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 4486US2023406959A1Stabilized formulations containing anti-pcsk9 antibodiesREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4585US11098127B2Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodiesREGENERON PHARMA·Filed 2018·Granted Aug 24, 2021·1 cites·27 claims
- 4684US12440622B2Devices and methods for overfilling drug containersREGENERON PHARMA·Filed 2024·Granted Oct 14, 2025·0 cites·20 claims
- 4784US2024415969A1Process for reducing subvisible particles in a pharmaceutical formulationREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4882US7365165B2IL-1 antagonist formulationsREGENERON PHARMA·Filed 2005·Granted Apr 29, 2008·8 cites·13 claims
- 4981US11918785B2Devices and methods for overfilling drug containersREGENERON PHARMA·Filed 2023·Granted Mar 5, 2024·0 cites·17 claims
- 5080US2021252147A1VEGF Antagonist FormulationsREGENERON PHARMA·Filed 2021·Application pending·0 cites
Showing the top 50 of 71 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Daniel Dix files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →